Abstract 134P
Background
INCB099318, an oral, programmed death ligand-1 (PD-L1) inhibitor, has shown preliminary efficacy and acceptable safety in an ongoing, Phase 1, open-label, multicenter study in patients with advanced solid tumors (Pinato, et al. SITC 2022). Here we present updated study results.
Methods
Eligible patients were ≥18 years with ECOG PS ≤1, who had disease progression after available treatment or were ineligible for/without access to standard treatment. In Part 1, doses were escalated from 100 mg BID using a Bayesian optimal interval design. Select doses were to be expanded in Part 2. Primary endpoints are INCB099318 safety, tolerability, and determination of pharmacologically active/maximum tolerated dose (MTD). Secondary and exploratory endpoints include pharmacokinetics, objective response rate per RECIST v1.1, and biomarkers of pharmacologic activity. Table: 134P
Safety
TEAEs, n (%) | Total patients (N=101) | |
Any grade | Grade ≥3 | |
All cause TEAEs | 94 (93.1) | 41 (40.6) |
Occurring in >10% of patients | ||
Fatigue | 33 (32.7) | 4 (4.0) |
Constipation | 24 (23.8) | 0 |
Nausea | 23 (22.8) | 2 (2.0) |
Anemia | 17 (16.8) | 9 (8.9) |
Decreased appetite | 15 (14.9) | 2 (2.0) |
Diarrhea | 15 (14.9) | 2 (2.0) |
Cough | 13 (12.9) | 0 |
Dyspnea | 13 (12.9) | 1 (1.0) |
Vomiting | 12 (11.9) | 1 (1.0) |
Alanine aminotransferase increased | 11 (10.9) | 2 (2.0) |
Immune-related TEAEs | 11 (10.9) | 4 (4.0) |
Serious TEAEs | 25 (24.8) | |
Occurring in >1 patient | ||
Anemia | 2 (2.0) | |
Cerebrovascular accident | 2 (2.0) | |
Grade ≥3 Treatment-related TEAEs | 11 (10.9) | |
Occurring in >1 patient | ||
Fatigue | 3 (3.0) | |
Anemia | 2 (2.0) |
Results
As of June 23, 2023, 101 patients had received INCB099318 at doses from 100 to 800 mg QD or BID (Part 1, n=64; Part 2, n=37). Median age was 58 years (range, 29-89), 59.4% were women, 86.1% were White, 68.3% had ≥2 prior lines of treatment, and 9.9% had prior IO. Most common tumor types were cervical (17.8%), ovarian (10.9%), and colorectal (5.9%). No dose-limiting toxicities were observed and MTD was not reached. In Part 2, 3 dose levels were expanded (400 mg BID, n=18; 800 mg BID n=14, 800 mg QD, n=5). Overall, 82 patients (81.2%) discontinued treatment, 69 (68.3%) due to disease progression. 94 (93.1%) patients had treatment-emergent adverse events (TEAEs) (Table). Several responses have been observed, and updated results will be presented.
Conclusions
INCB099318 was generally well tolerated at all doses tested. Preliminary safety and response outcomes support future development of INCB099318 for the treatment of select advanced solid tumors.
Clinical trial identification
NCT04272034.
Editorial acknowledgement
Editorial assistance was provided by Emily Sun and Andrew Marson-Neep of Envision Pharma Group (Philadelphia PA, USA).
Legal entity responsible for the study
Incyte Corporation, Wilmington, DE.
Funding
Incyte Corporation, Wilmington, DE.
Disclosure
D.J. Pinato: Financial Interests, Personal, Other, travel grant and advisory/speaker fees: AstraZeneca, Avammune, Bayer, Bristol Myers Squibb, Da Volterra, Eisai, Falk Pharma, H3 Biomedicine, Ipsen, Lift Biosciences, Mina Therapeutics, MSD Oncology, Mursla Bio, Roche, Roche/Genentech, Starpharma, ViiV Healthcare; Financial Interests, Institutional, Research Funding: Bristol Myers Squibb, GSK, MSD Oncology; Financial Interests, Personal, Other: Wiley. U. Banerji: Financial Interests, Personal, Other, travel grant and advisory fees: Bayer, Boehringer Ingelheim, Janssen, Pegascy, Sierra Oncology; Financial Interests, Institutional, Research Funding: AstraZeneca, BTG, Carrick Therapeutics, Chugai Pharma, Onyx, Verastem. S. Rottey: Financial Interests, Personal, Other, travel grants and advisory/speaker fees: Novartis, Roche, Pfizer, MSD, Bristol Myers Squibb, Ipsen; Financial Interests, Personal, Research Grant: Roche, MSD. K. Peltola: Financial Interests, Personal, Advisory Board: MSD, Ipsen, Roche, BMS, Pfizer, Lilly, Novartis, Bayer; Financial Interests, Personal, Stocks/Shares: Faron Pharmaceuticals; Financial Interests, Institutional, Local PI, Conduct of sponsored clinical trial: Novartis; Financial Interests, Institutional, Local PI, Sponsored clinical trial: Exelixis; Financial Interests, Institutional, Local PI, Several clinical trials: BMS, MSD, Roche; Financial Interests, Institutional, Local PI, clinical trials: Incyte; Financial Interests, Institutional, Local PI, Conduct of clinical trials: Pfizer; Financial Interests, Institutional, Local PI, Conduct of clinical trial: Bayer. R. Kristeleit: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Clovis Oncology, GSK and Incyte ; Financial Interests, Personal, Other, Travel grant: AstraZeneca, GSK and Sierra Oncology ; Financial Interests, Personal, Research Grant: MSD; Financial Interests, Personal, Speaker, Consultant, Advisor: Basilea Pharmaceutica and Shattuck Pharma. M. Gutierrez: Financial Interests, Personal, Other, travel grand and speaker fees: BMS, Guardant Health, Lilly, Merck; Financial Interests, Personal, Stocks or ownership: Cota Healthcare; Financial Interests, Institutional, Research Funding: Acerta Pharma, Adlai Nortye, Arcus Biosciences, Array BioPharma, Bayer, Bellicum Pharmaceuticals, BMS, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, Compass Therapeutics, Constellation Pharmaceuticals, Cullinan Oncology, Cyteir, Daiichi Sankyo. S.N. Symeonides: Financial Interests, Institutional, Speaker, Consultant, Advisor: Bicycle Therapeutics, Boxer Capital, Bristol Myers Squibb, Duke Street Bio, Eisai, Ellipses Pharma, Eugit Therapeutics, EUSA Pharma, Exscientia, Ipsen, MedAnnex, MSD, Pfizer/EMD Serono, Vaccitech; Financial Interests, Personal, Other, Travel Grant: BioNTech, Bristol Myers Squibb, EUSA Pharma, Ipsen, MSD; Financial Interests, Institutional, Research Funding: MSD and Verastem. M. Hoejgaard: Financial Interests, Institutional, Research Funding: Puma Biotechnology, Roche/Genentech, AstraZeneca, Incyte, Pfizer, Orion Pharma, MSD, Merck, Bristol Myers Squibb, Novartis, Lilly Pharmaceuticals/ Loxo Oncology, Bayer/Loxo Oncology, Amgen, Repare Therapeutics, Genmab, Kinnate Biopharma; Financial Interests, Personal, Stocks/Shares: Bavarian Nordic, Agilent, Illumina, Pacific Biosciences; Financial Interests, Personal, Other, Board Member: Danish Medicines Council. V. Ebiana, J. Daniel, J. Pulini: Financial Interests, Personal, Full or part-time Employment: Incyte Corporation; Financial Interests, Personal, Stocks or ownership: Incyte Corporation. All other authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display